A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer  

作　　者：Duo Wang Jun Zhou Weimin Fang Cuiqing Huang Zerong Chen Meng Fan Ming-Rong Zhang Zeyu Xiao Kuan Hu Liangping Luo 

机构地区：[1]Medical Imaging Center,The First Affiliated Hospital of Jinan University,Guangzhou,510632,PR China [2]The Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation,Jinan University,Guangzhou,510632,PR China [3]Department of Advanced Nuclear Medicine Sciences,Institute of Quantum Medical Science,National Institutes for Quantum and Radiological Science and Technology,Chiba,263-8555,Japan [4]Center for Nanomedicine and Department of Anesthesiology,Brigham and Women’s Hospital,Harvard Medical School,Boston,MA,02115,USA

出　　处：《Bioactive Materials》2022年第7期312-323,共12页生物活性材料（英文）

基　　金：This study was supported partly by grants from the Natural Science Foundation of China(81771973,81971672 and 82102005);Key Program of the Natural Science Foundation of Guangdong Province(2018B0303110011);Guangzhou Key Laboratory of Molecular and Functional Imaging for Clinical Translation(201905010003);Fundamental Research Funds for the Central Universities(21620308 and 21620101);JSPS KAKENHI grant Nos.21H02873,21K07659,and 20H03635;the AMED Moonshot Research and Development Program(Grant No 21zf0127003h001).

摘　　要：Epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKI),such as Erlotinib,have demonstrated remarkable efficacy in the treatment of non-small cell lung cancer(NSCLC)patients with mutated EGFR.However,the efficacy of EGFR-TKIs in wild-type(wt)EGFR tumours has been shown to be marginal.Methods that can sensitize Erlotinib to EGFR wild-type NSCLC remain rare.Herein,we developed a multifunctional superparamagnetic nanotheranostic agent as a novel strategy to potentiate Erlotinib to EGFR-wt NSCLCs.Our results demonstrate that the nanoparticles can co-escort Erlotinib and a vascular epithermal growth factor(VEGF)inhibitor,Bevacizumab(Bev),to EGFR-wt tumours.The nanotheranostic agent exhibits remarkable effects as an inhibitor of EGFR-wt tumour growth.Moreover,Bev normalizes the tumour embedded vessels,further promoting the therapeutic efficacy of Erlotinib.In addition,the tumour engagement of the nanoparticles and the vascular normalization could be tracked by magnetic resonance imaging(MRI).Collectively,our study,for the first time,demonstrated that elaborated nanoparticles could be employed as a robust tool to potentiate Erlotinib to EGFR-wt NSCLC,paving the way for imaging-guided nanotheranostics for refractory NSCLCs expressing EGFR wild-type genes.

关 键 词：Non-small cell lung cancer EGFR wild-Type Superparamagnetic iron oxide ERLOTINIB BEVACIZUMAB Tumour vascular normalization 

分 类 号：R734.2[医药卫生—肿瘤] R318[医药卫生—临床医学]